Bellerophon Therapeutics is a
clinical-stage biotherapeutics company.
We are focused on developing innovative therapies in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
More About Us
Bellerophon Therapeutics COVID-19 Statement
As news about COVID-19 continues to unfold, the safety and well-being of our employees, as well as the patients and the healthcare professionals we serve in and outside of hospital settings, is of the upmost importance to Bellerophon Therapeutics during these unprecedented times.
On March 20, 2020, the FDA granted emergency expanded access allowing our proprietary inhaled nitric oxide (iNO) delivery system, INOpulse®, to immediately be used for the treatment of COVID-19. Based on the genetic similarities between SARS-CoV and COVID-19, results from SARS-CoV clinical studies support the potential for iNO to provide meaningful benefit for patients infected with COVID-19. Treatment with the INOpulse system was initiated for the first time in a patient with a diagnosis of COVID-19 at the end of March 2020.
For more information on our Expanded Access program, please call 908-574-4770 or email EAP@Bellerophon.com.
The Bellerophon Therapeutics team will continue to work closely with the FDA to make INOpulse available to more patients around the U.S. under the Expanded Access program in our collective fight against the pandemic. More updates will be shared about our clinical development progress at a later date.
Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc). Our goal is to become a leader in developing and commercializing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. |
Bellerophon Therapeutics Inc. News ReleaseA Collection of Bellerophon Therapeutics Inc. News Release Bellerophon to Present at the H.C. Wainwright Global Life Sciences Conference
03/02/2021 01:30 PM
WARREN, N.J. , March 02, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
01/04/2021 01:30 PM
WARREN, N.J. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum , Chief Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease
12/01/2020 01:30 PM
WARREN, N.J. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19
11/23/2020 01:30 PM
WARREN, N.J. , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the independent Data Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference
11/11/2020 01:30 PM
WARREN, N.J. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum , Chief More News |
|
|
|
 Our goal is to become a leader in developing and commercializing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. |
Bellerophon Therapeutics Inc. News ReleaseA Collection of Bellerophon Therapeutics Inc. News Release Bellerophon to Present at the H.C. Wainwright Global Life Sciences Conference
03/02/2021 01:30 PM
WARREN, N.J. , March 02, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
01/04/2021 01:30 PM
WARREN, N.J. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum , Chief Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease
12/01/2020 01:30 PM
WARREN, N.J. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19
11/23/2020 01:30 PM
WARREN, N.J. , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the independent Data Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference
11/11/2020 01:30 PM
WARREN, N.J. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum , Chief |